Oragenics Announces Pricing of Public Offering
- None.
- None.
Insights
The recent public offering by Oragenics, Inc. indicates a strategic move to secure funding for the continued development of their neurosteroid drug compound, ONP-002. From a financial perspective, the pricing of shares at $1.50 to raise $2.1 million, before expenses, suggests a targeted approach to finance specific corporate objectives. The decision to provide underwriters with an over-allotment option is a common practice known as a 'greenshoe' option, which can help stabilize the stock price post-offering. The potential dilution effect on current shareholders is an important consideration, as it could impact the stock's price performance in the short term.
Investors and analysts will be monitoring the deployment of the raised capital towards ONP-002's development, as its success or failure will likely have significant implications for the company's financial health and stock valuation. The use of a shelf registration statement expedites the process of capital raising, demonstrating the company's preparedness to leverage market opportunities promptly.
ONP-002's role in treating mild traumatic brain injuries, commonly known as concussions, places Oragenics in a niche yet crucial segment of the pharmaceutical market. The development of treatments for neurological disorders, particularly concussions, is an area of high unmet medical need and significant commercial potential. Given the prevalence of concussions in sports and other activities, a successful treatment could lead to substantial market demand.
Furthermore, the intranasal delivery system of their pharmaceuticals could offer a competitive advantage in terms of ease of administration and rapid absorption, which is critical in acute neurological conditions. The progress of ONP-002 through clinical trials and eventual market approval will be key milestones that could greatly affect the company's future prospects and investor sentiment.
Analyzing the broader market context, Oragenics' public offering should be viewed against the backdrop of the biotech industry's funding landscape. Biotech firms often rely on public offerings to fund research and development due to the capital-intensive nature of the industry. The timing and success of such offerings can be influenced by market conditions, investor appetite for risk and the perceived potential of the company's drug pipeline.
The market's reception of the offering and the subsequent performance of Oragenics' stock will provide insights into investor confidence in the company's strategic direction. It will also reflect the market's assessment of the risk-reward profile associated with investing in a single-asset biotech company, which is inherently higher risk due to the binary outcomes associated with clinical trial results.
The Company intends to use the net proceeds from the offering to fund the continued development of ONP-002, which is a unique neurosteroid drug compound intended to treat mild traumatic brain injuries also known as concussions, and for general corporate purposes and working capital.
ThinkEquity and Laidlaw & Company (
The securities are being offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-269225), including a base prospectus, filed with the Securities and Exchange Commission (the “SEC”) on January 13, 2023 and declared effective on January 25, 2023. The offering is being made only by means of a written prospectus. A final prospectus supplement and accompanying base prospectus describing the terms of the offering will be filed with the SEC and available on its website at www.sec.gov. Copies of the final prospectus supplement and the accompanying base prospectus relating to the offering may also be obtained, when available, from the offices of ThinkEquity, 17 State Street, 41st Floor,
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Oragenics
Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as well as proprietary powder formulation and an intranasal delivery device. For more information, please visit www.oragenics.com.
Forward Looking Statements
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” "will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the Company’s public filings and in the documents incorporated or deemed to be incorporated by reference therein. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227469715/en/
Oragenics, Inc.
Janet Huffman, Chief Financial Officer
813-286-7900
jhuffman@oragenics.com
Source: Oragenics, Inc.
FAQ
How many shares of common stock were offered in the public offering by Oragenics, Inc. (OGEN)?
What is the public offering price per share set by Oragenics, Inc. (OGEN)?
How much gross proceeds did Oragenics, Inc. (OGEN) raise from the public offering?
What is the intended use of the net proceeds from the public offering by Oragenics, Inc. (OGEN)?
Who are the joint book-running managers for the public offering by Oragenics, Inc. (OGEN)?
